相关实验视频

Updated: May 11, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

对EGFR抑制剂对NSCLC的耐药性研究动态的视觉分析

Jun Shao¹, Yunru Gu¹, Renhua Guo¹

¹Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.

Drug design, development and therapy

|July 1, 2024

概括

在非小细胞肺癌 (NSCLC) 中对表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 耐药性的研究正在迅速增长. 本文献分析绘制了全球研究趋势和EGFR-TKI耐药性的关键贡献者.

科学领域:

在瘤学瘤学.
生物标志物生物标志物
药理学药理学是指药理学的学科.

背景情况:

表皮生长因子受体 (EGFR) 的激活突变是EGFR氨酸激酶抑制剂 (TKI) 治疗非小细胞肺癌 (NSCLC) 的预测生物标志物.
对EGFR-TKI的治疗耐药性构成一个重大挑战,需要对耐药性机制和耐药后策略有更深入的了解.
对EGFR突变NSCLC的研究对于推进新型治疗方法至关重要.

研究的目的:

进行对NSCLC中EGFR-TKIs耐药性的研究趋势的文献分析.
确定EGFR-TKI耐药性领域的关键研究领域,有影响力的作者,机构和期刊.
为克服EGFR-TKI耐药性的未来研究方向提供指导.

主要方法:

从科学网络核心集合 (WoSCC) 收集的关于NSCLC中EGFR-TKI耐药性的5866份文档的文献分析.
利用了包括CiteSpace和VOSviewer在内的文献计量工具进行全面的分析和可视化.
审查的出版物产出,引用数量,地理分布,机构贡献和作者影响.

主要成果:

自2016年以来出版物的显著增加表明研究兴趣日益增长.
中国在出版量方面领先,而美国在引用影响方面领先.
关键的研究主题包括遗传测试,耐药性机制和耐药性后治疗策略.

结论:

该研究提供了关于NSCLC中EGFR-TKI耐药性的研究环境的全面概述.
确定有影响力的贡献者和新兴趋势,以指导未来的研究工作.
强调需要继续研究了解和克服抗药性机制,以改善患者的治疗结果.

关键词:

在 EGFR 基因突变.欧洲农业基金的技术技能.在NSCLCLC中,我们可以看到.文献计量分析的分析热点热点的地方.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...